FAQ

MK-0657

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2018
01220092018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Convergent Mechanisms Underlying Rapid Antidepressant Action.
Traditional pharmacological treatments for depression have a delayed therapeutic onset, ranging from several weeks to months, and… (More)
Is this relevant?
2017
2017
A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms…
OBJECTIVES Blockade of N-methyl-D-aspartate receptors containing the NR2B subunit has been shown to be therapeutic in animal… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Review
2016
Review
2016
Role of calcium, glutamate and NMDA in major depression and therapeutic application.
Major depression is a common, recurrent mental illness that affects millions of people worldwide. Recently, a unique fast… (More)
Is this relevant?
2015
2015
Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice.
N-methyl-D-aspartate (NMDA) receptor antagonists, including open channel blockers and GluN2B receptor subtype selective… (More)
Is this relevant?
2015
2015
Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test.
OBJECTIVE The N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine, produces rapid and enduring antidepressant effect in… (More)
  • figure 1
Is this relevant?
Review
2015
Review
2015
Ketamine and other potential glutamate antidepressants.
The need for rapid acting antidepressants is widely recognised. There has been much interest in glutamate mechanisms in major… (More)
Is this relevant?
Review
2014
Review
2014
Targeting of NMDA receptors in the treatment of major depression.
Major depressive disorder (MDD) is a common, recurrent mental illness that affects millions of people worldwide. Accumulating… (More)
Is this relevant?
Review
2014
Review
2014
NMDA antagonists under investigation for the treatment of major depressive disorder.
INTRODUCTION Mood disorders, including depression, are becoming increasingly prevalent in the developed world. Furthermore… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder.
Converging lines of evidence suggest that the glutamatergic system may play an increasingly important role in the development of… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2009
2009
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
The glutamatergic system is thought to contribute to the motor disturbances observed in Parkinson's disease. Blockade of… (More)
  • table I
  • table II
  • figure 1
  • figure 2
  • figure 3
Is this relevant?